BLCO Price Prediction Next Week
Technical Analysis
Based on recent price action, BLCO has formed an ascending triangle pattern with resistance at $16.60 and support at $15.62. The stock is currently trading at $15.98, showing increased volatility with higher trading volume of 1.24M shares compared to its average.
News Impact Recent announcement of FY2025 revenue guidance between $4.95-5.05 billion aligns with analyst expectations of $5.02 billion. The company also projects adjusted EBITDA of $900-950 million for FY2025. Additionally, news about considering "a full separation" from Bausch Health Companies Inc. but not resulting in a deal has created some uncertainty in the market.
Price Prediction for Next Week Based on technical indicators and news sentiment:
- Resistance levels: $16.60, $17.00
- Support levels: $15.62, $15.20
- Target price range: $15.50 - $16.80
Trading Recommendation SELL with target price of $15.50 Rationale:
- Bearish divergence on momentum indicators
- Increased selling pressure near resistance
- Uncertainty around corporate restructuring
- Stock trading below 20-day moving average
- High volume on recent pullbacks suggests distribution
Set stop loss at $16.85 to manage risk.
BLCO Similar Chart Price Prediction
The price of BLCO is predicted to go up -0.6%, based on the high correlation periods with HII. The similarity of these two price pattern on the periods is 95.74%.
BLCO
HII
Down: -0.6%Similarity: 95.74%
BLCO Revenue Forecast
BLCO EPS Forecast
BLCO FAQs
What is bull’s view on BLCO?
What is bear's view on BLCO?
What is BLCO revenue forecast for next quarter？
What is BLCO eps forecast for next quarter？
BLCO VS S&P500
As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.
With an upcoming launch of multifocal and toric lenses in the Infuse line (daily silicone hydrogels), we expect Bausch to win over some new customers as well as to have its current Bausch lens wearers upgrade.
We expect patents and product superiority of Biotrue eye drops, Lumify, and PreserVision to secure Bausch as a leader in the over-the-counter eye care and supplements space.
BLCO Analyst's Forecast
Joanne Wuensch
Citigroup
Strong Buy → Hold
2024-12-11
Price Target
$24 → $22
Upside
+21.21%
Citi downgraded Bausch + Lomb to Neutral from Buy with a price target of $22, down from $24. The firm sees "competing pressures" on the company. On the one hand, Bausch seems to have the pieces to put together "another nice year" and current estimates for fiscal 2025 are reasonable, the anlayst tells investors in a research note. On the other, the firm says Bausch + Lomb's ownership has been an overhang and the potential takeout providing potential upside to the stock "may or may not materialize."
Patrick Wood
Morgan Stanley
Buy → Hold
2024-12-02
Price Target
$19
Downside
-2.61%
Larry Biegelsen
Wells Fargo
Buy
2024-10-31
Price Target
$23 → $26
Upside
+28.21%
